论文部分内容阅读
目的观察复方异丙托溴铵和布地奈德氧驱动雾化吸入治疗毛细支气管炎的疗效。方法将56例毛细支气管炎患儿随机分成治疗组30例和对照组26例。2组均采用综合治疗。治疗组在此基础上,予异丙托溴铵0.50mg和硫酸沙丁胺醇3.0mg(可比特1.25mL)和普米克令舒2mL(布地奈德1mg)氧驱动雾化吸入,2、3次·d-1,每次约5min。对照组雾化吸入地塞米松磷酸钠注射液2mg和9g·L-1盐水5mL,2次·d-1,每次约10min。结果治疗组咳嗽、气急、喘憋、肺部体征消失天数及平均住院天数与对照组比较差异均有统计学意义(Pa<0.05)。治疗组总有效率为96.6%,对照组总有效率为65.4%,2组总有效率比较差异有统计学意义(P<0.01)。结论复方异丙托溴铵和布地奈德氧驱动雾化吸入起效快,效果肯定,顺应性好,可作为婴幼儿毛细支气管炎的首选治疗。
Objective To observe the curative effect of compound ipratropium bromide and budesonide oxygen inhalation on bronchiolitis. Methods Fifty-six children with bronchiolitis were randomly divided into treatment group (n = 30) and control group (n = 26). 2 groups were treated with comprehensive treatment. On the basis of this, the treatment group received inhalation of 0.50 mg of ipratropium bromide and 3.0 mg of salbutamol sulfate (1.25 mL of comparable) and 2 mL of bupropion (budesonide 1 mg) -1, each about 5min. The control group was inhaled dexamethasone sodium phosphate injection 2mg and 9g · L-1 saline 5mL, 2 times · d-1, each about 10min. Results The treatment group cough, shortness of breath, wheezing, disappearance of lung signs and the average length of stay in hospital compared with the control group were statistically significant (Pa <0.05). The total effective rate was 96.6% in the treatment group and 65.4% in the control group. The total effective rate in the two groups was significantly different (P <0.01). Conclusion Compound ipratropium bromide and budesonide oxy-activated aerosol inhalation has the advantages of fast onset, definite effect and good compliance, which can be used as the first choice for the treatment of bronchiolitis in infants and young children.